0.05
-9.09%
Close of 6 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hemostemix
Its shares trade on TSX Venture under the ticker HEM.V. It has been listed since 20 December 2012.
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The firm has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The firm holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Dec 2012
- Website
- hemostemix.com ↗
Leadership
Pay as last reported
- Mr. Peter LaceyIndependent Chairman of the Board
- Mr. Thomas SmeenkPresident, Chief Executive Officer, Director, since 2019C$277,077
- Ms. Christina WuInterim Chief Financial OfficerC$69,267
- Ms. Sana FarooquiChief Marketing Officer
- Mr. Croom LawrenceChief Commercial Officer
- Dr. Ronnie HershmanIndependent Director
- Mr. Loran SwanbergIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hemostemix has 87 patents on stem cell lineages from patient blood.
- ACP-01 is in Phase 2 trials for critical limb ischemia in Canada and the US.
- Hemostemix's technology enables personalized regenerative therapy within seven days.
Weaknesses
- Hemostemix's lead candidate ACP-01 is still in Phase 2 clinical trials.
- The company has no commercialized products yet as it is clinical-stage.
- Hemostemix's subsidiaries include Kwalata Trading Limited and PreCerv Inc.
Opportunities
- Hemostemix could expand ACP-01 trials to more countries after Phase 2 success.
- The growing biotechnology sector in Canada offers potential partnerships.
- Hemostemix's stem cell platform may apply to other ischemic diseases.
Threats
- Hemostemix faces competition from other biotech firms in ischemic disease treatments.
- Regulatory approval delays could impact ACP-01's timeline.
- Hemostemix's reliance on a single clinical-stage candidate ACP-01 poses risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.